The governments streamlined approval processes for breakthrough therapies enable quicker market entry, supporting demand growth in urban centers
Insulin-like growth factor-2)
Hengrui and Kailera report positive phase 3 results for dual GLP-1/GIP agonist in obesity treatment HRS9531 achieves significant weight reduction in Phase 3 trial, with plans for NDA submission in China and global development as KAI-9531 Hengrui Pharma and Kailera Therapeutics, have announced positive topline results from the Phase 3 clinical trial (HRS9531-301) of HRS9531, a once-weekly injectable dual GLP-1/GIP receptor agonist for adults with obesity or overweight
Human growth hormone (HGH), also called somatotropin, is a hormone that the pituitary gland, which is about the size of a pea and found at the base of your brain, makes and releases
Done correctly, it yields a stable, soluble solution ready for cell culture or preclinical assay work
Prescription Medications for Persistent Constipation For cases of severe or chronic constipation that do not respond to lifestyle changes or over-the-counter remedies, your healthcare provider may consider prescribing stronger medications
